Retatrutide FDA Status 2026: What the RFK Reclassification Means
Not yet FDA-approved — currently in Phase 3 clinical trials.
The 2026 Reclassification Timeline
FDA moves 19 peptides — including Retatrutide — to Category 2, effectively ending legal 503A compounding access. Concerns cited: immunogenicity risk, peptide-related impurities, limited human safety data.
HHS Secretary Robert F. Kennedy Jr announces on Joe Rogan Experience #2461 that approximately 14 of the 19 restricted peptides will move from Category 2 back to Category 1.
FDA announces the Pharmacy Compounding Advisory Committee (PCAC) will convene July 23–24, 2026 to review specific peptides for the 503A Bulks List.
FDA PCAC meets. Six of seven reviewed peptides recommended for inclusion on the 503A Bulks List. Committee recommendations are advisory, not binding.
As of August 2026, the FDA has not published the final formal reclassification. Once formalised, licensed 503A compounding pharmacies will be able to prepare reclassified peptides for patients with valid prescriptions.
What This Means for Retatrutide Patients
Retatrutide is a novel triple agonist (GLP-1 / GIP / glucagon) in Phase 3 trials with Eli Lilly. It is not FDA-approved and is not legally available for compounding under Section 503A. Any "retatrutide" sold on the gray market is unregulated and not clinically supervised.
Peptides sold online labeled "for research use only" are not manufactured under pharmaceutical quality standards, are not USP 797 sterile-compounded, and lack physician oversight. The 2026 reclassification is intended to restore access through licensed 503A pharmacies — not to legitimise the gray market.
ClinicalTrials.gov (Lilly Phase 3 studies)
Ready for Retatrutide? Compare Licensed 503A Pharmacies
Once you have a valid prescription, Script Unlock lets verified 503A / 503B sterile compounding pharmacies bid on your prescription. Compare prices from licensed pharmacies — never the gray market.
Editorial note: Content on this page is informational only and is not medical advice. Regulatory status may change; verify with a licensed pharmacist or the FDA 503A Bulks List directly. Reviewed by the Script Unlock Pharmacy Verification Team.